Skip to main content

Table 1 Patient characteristics

From: No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache

Group

Patient #

Primary symptom/diagnosis

Secondary diagnosis

Weeks since COVID-19 infection

Age (years)

Gender

Neurological exam

cMRI

CSF

Persistent Post-COVID-19 headache

1

Headache

Migraine

32

49

Female

Normal

n.a

No inflammatory change

2

Headache

Recurrent syncopes

16

23

Female

Normal

Normal

No inflammatory change

3

Headache

None

52

46

Female

Normal

Normal

No inflammatory change

4

Headache

Bechterew’s disease

23

36

Female

Fasciculations right M. vastus med

Normal

No inflammatory change

5

Headache

Migraine

55

49

Female

Normal

Normal

No inflammatory change

6

Headache

None

21

51

Female

Normal

n.a

No inflammatory change

Mild COVID-19

7

Encephalopathy

Chronic heart disease, CAD, hyper-cholesterinemia, asthma

60

64

Male

Delirium, reduced vigilance, attention deficit, confusion, agitation

Normal

No inflammatory change

8

Impaired gait

Hyperthyreosis, reflux

0

64

Male

Sensory ataxia

Microangio-pathy

No inflammatory change

9

Encephalopathy

Pneumonia, carotid stenosis

2.5

74

Female

Somnolence, increased muscle tone

Normal

No inflammatory change

10

Dyspnea

Hypothyreosis, hypertension

1

47

Female

Normal

n.a

n.a

11

Dyspnea

AV block °I

10

60

Male

Normal

n.a

n.a

12

Cough

Diabetes type II, nephropathy, hypertension, dementia

3

86

Female

Normal

n.a

n.a

13

Dyspnea

None

1

42

Female

Normal

n.a

n.a

14

Dyspnea

COPD, CAD, renal insufficiency

3

63

Female

n.a

n.a

n.a

15

Cold symptoms

Liver transplant, hepatitis C, renal insufficiency, osteoporosis, Diabetes type II

0

51

Male

Normal

n.a

n.a

16

Fever

Agammaglobuliemia

1

29

Male

Normal

n.a

n.a

17

Perineuritis n. optici

None

4

33

Male

Reduced vision

Perineuritis nervi optici

No inflammatory change

18

Impaired vision

Allergic asthma

62

42

Female

Normal

Normal

No inflammatory change

19

Impaired gait

None

65

75

Female

Sensory ataxia

n.a

n.a

20

PNP

Hypertension

17

52

Female

Sensory ataxia

n.a

n.a

21

Impaired gait

Asthma, cutaneous t-cell lymphoma, acantholytic dermatosis

2

60

Male

Sensory ataxia

n.a

n.a

22

Cold symptoms

None

2

31

Female

n.a

n.a

n.a

23

Cold symptoms

COPD

2.5

65

Male

Normal

n.a

n.a

Severe COVID-19

24

Cold symptoms

Prostate cancer

1

65

Male

Normal

n.a

n.a

25

Dyspnea

Stroke, atrial fibrillation, hypertension,

1

84

Female

Different focal neurological deficits

n.a

n.a

26

Syncope

Aortic aneurysm, sleep apnea, aortic valve replacement, hypercholesterolemia

1

53

Male

Horner syndrome right side, sensory deficit left lower arm

n.a

n.a

27

Dyspnea

Renal insufficiency, CAD, peripheral artery disease, atrial fibrillation, prostate cancer, hyperlipidemia, diabetes type II

1

84

Male

Reduced vigilance

n.a

n.a

28

Dyspnea

Autoimmune hepatitis, hypothyreosis, liver fibrosis, esophageal varices

0

54

Female

normal

n.a

n.a

29

Cold symptoms

CAD, hypertension, diabetes type II

1

82

Female

General weakness

n.a

n.a

30

Dyspnea

Cardiomoypathy, CLL, hypercholesteremia, cardiomyopathy, mitral regurgitation °I

2

82

Female

Normal

n.a

n.a

31

Dyspnea

Perimyocarditis, atrial fibrillation, critical illness myopathy

64

68

Female

Hypesthesia

n.a

n.a

32

Dyspnea

Autoimmune hepatitis, Hashimoto Thyroiditis, hypertension, COPD, critical illness myopathy

4

64

Female

Sensory ataxia

n.a

n.a

33

Cold symptoms

Hypertension, diabetes type II, restless legs syndrome, hypothyreosis

3

76

Female

n.a

n.a

n.a

34

Dyspnea

Heart Failure, atrial fibrillation, hypertension, Diabetes mellitus II, CAD, hyperlipidemia

4

77

Female

External oculo-motor nerve palsy

n.a

No inflammatory change

COVID-19-negative controls

35

PPA

Gonarthrosis, hypercholesterinemia, hyperhomocysteinemia, glaucoma

0

62

Female

Cognitive deficits

Temporal lobe atrophy

No inflammatory change

36

Idiopathic intracranial hypertension

Asthma, thyroid carcinoma, sarcoidosis

0

42

Female

Normal

n.a

No inflammatory change

37

Idiopathic intracranial hypertension

None

0

32

Male

Normal

n.a

n.a

38

Headache

None

0

39

Male

Normal

n.a

n.a

39

None

None

0

27

Female

Normal

n.a

n.a

40

None

Diabetes mellitus II

0

34

Female

Normal

n.a

n.a

41

Polyneuropathy

obstructive sleep apnea, hypogonadotropic hypogonadism

0

57

Male

Sensory ataxia

n.a

n.a

42

Seizure

Structural epilepsy, asthma, Spondylose deformans, hypertension

0

73

Male

Reduced vigilance

n.a

n.a

43

n.a

n.a

n.a

n.a

n.a

n.a

n.a

n.a

44

n.a

n.a

n.a

n.a

n.a

n.a

n.a

n.a

45

n.a

n.a

n.a

n.a

n.a

n.a

n.a

n.a

46

n.a

n.a

n.a

n.a

n.a

n.a

n.a

n.a

47

n.a

Hemophilia A, liver transplant, polyneuropathy, renal insufficiency

0

68

Male

n.a

n.a

n.a

48

Cold symptoms

None

0

37

Female

Normal

n.a

n.a

  1. Some clinical data were not available due to ethics proposal restrictions
  2. COPD chronic obstructive pulmonary disease, cMRI cerebral magnetic resonance imaging, CSF cerebrospinal fluid, CAD coronary artery disease, CLL chronic lymphocytic leukemia, PPA primary progressive aphasia, n.a. not applicable